Augmentin


Also found in: Dictionary, Medical, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Augmentin

an antibiotic

References in periodicals archive ?
We have good stock of all the four concentrates of children's Augmentin in store and we are still selling it to customers who present a doctor's prescription.
The agency also mentioned that the Hong Kong government had said that tests done on Augmentin syrup -- a joint British, French product -- contained unsafe plastic products known as DIDP.
Augmentin was pulled off shelves in Hong Kong due to the product containing
The lawsuit alleged that GlaxoSmithKline filed illegal double patents on Augmentin in order to lock generic competitors out of the Augmentin market, depriving consumers of cheaper generic versions of the drug.
Sales of another key drug, Augmentin, slipped 29pc during last year to pounds 825m with the group losing a court battle in the US over patent rights.
GlaxoSmithKline saw its 19-month battle over patent rights for its Augmentin anti- biotic fail on November 24 after a federal court upheld earlier rulings that its US patents were invalid.
GlaxoSmithKline confounded market watchers who predicted its shares would come under pressure after the drugs giant said it had lost an appeal over patent rights in the US for its antibiotic drug Augmentin, rising 6p to 1373p.
2:01-CV-391; 2:01-CV-677; and 2:01-CV-925) invalidating a total of seven patents claiming GlaxoSmithKline PLC's ("Glaxo's") antibiotic Augmentin (amoxicillin, clavulanate potassium).
The review authors recommended avoiding [beta]-lactam antibiotics in women at risk for preterm delivery because one trial found a higher rate of necrotizing enterocolitis with Augmentin (amoxicillin /clavulanate).
Pharmaceuticals group GlaxoSmithKline's first quarter figures on Wednesday are likely to have been affected by the weakness of the US dollar and generic competition to its Augmentin anti-bacterial drug.
Glaxo faced rivals to its antibiotic Augmentin from autumn 2002.
nPharmaceuticals group GlaxoSmithKline's fourth quarter is expected to have been its toughest of the year after suffering from the impact of the weak US dollar and the launch of competition to its antibiotic Augmentin.
GSK has been rocked by competition concerns regarding one of its key drugs, antibiotic Augmentin, after a US court ruled the patents were invalid.